The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
SEZanne: A phase 2 randomized, open-label, multicenter study to evaluate the optimal dose, safety, and efficacy of ABBV-706 in combination with atezolizumab (atezo) versus standard of care (SOC) in patients (pts) with previously untreated extensive-stage (ES) small cell lung cancer (SCLC).
 
Kristof Cuppens
Consulting or Advisory Role - Abbvie; Amgen; AstraZeneca/MedImmune; Bristol-Myers Squibb; Daiichi Sankyo Europe GmbH; ITeos Therapeutics; Janssen; MSD; Pierre Fabre; Roche/Genentech
Research Funding - AstraZeneca (Inst)
Expert Testimony - Abbvie; AstraZeneca; MSD; Roche/Genentech
Travel, Accommodations, Expenses - AstraZeneca; Daiichi Sankyo Europe GmbH; Janssen; MSD; Roche/Genentech
 
Lauren Byers
Honoraria - Clinical Care Options; UpToDate
Consulting or Advisory Role - Abbvie; Amgen; AstraZeneca; Boehringer Ingelheim; Chugai Pharma; Daiichi Sankyo; Genentech; Jazz Pharmaceuticals; Novartis; Puma Biotechnology
Research Funding - Amgen (Inst); AstraZeneca (Inst); Jazz Pharmaceuticals (Inst)
Patents, Royalties, Other Intellectual Property - Methods and systems for diagnosis, classification, and treatment of small cell lung cancer and other high grade neuroendocrine carcinomas (Priority date: 3/3/2021); Molecular subtyping of small cell lung cancer to predict therapeutic responses (US Patent No.: 11,732,306; Priority Date 9/3/2019; Issue Date 8/22/2023)
 
Yasushi Goto
Honoraria - Amgen; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb Japan; Chugai Pharma; Daiichi Sankyo/Astra Zeneca; Daiichi Sankyo/UCB Japan; Janssen; Lilly Japan; Merck; MSD; Nichiiko; Novartis; Ono Pharmaceutical; Pfizer; Sandoz; Taiho Pharmaceutical; Takeda; Thermo Fisher Scientific; Towa Pharmaceutical
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; Chugai Pharma; Daiichi Sankyo/UCB Japan; GlaxoSmithKline; Janssen; Jazz Pharmaceuticals; Kyowa Kirin International; Lilly; MSD; Novartis; Ono Pharmaceutical; Pfizer; Summit Health; Taiho Pharmaceutical
Research Funding - Abbvie (Inst); Amgen (Inst); Astellas Amgen BioPharama (Inst); AstraZeneca (Inst); Bayer (Inst); Bristol-Myers Squibb Japan (Inst); Chugai Pharma (Inst); CMIC (Inst); Daiichi Sankyo (Inst); Daiichi Sankyo/UCB Japan (Inst); EP Croit Co. (Inst); EPS Holdings (Inst); Genomic Health (Inst); IQvia (Inst); Janssen (Inst); Lilly Japan (Inst); Medpace (Inst); Merck Serono (Inst); MSD (Inst); Novartis (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst); Preferred Network (Inst); Sysmex (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst)
(OPTIONAL) Uncompensated Relationships - Cancer Net Japan; JAMT
 
Andrea Ardizzoni
Honoraria - Abbvie; Amgen; AstraZeneca; Bristol-Myers Squibb; Daiichi Sankyo; Gilead Sciences; Janssen; Lilly; Merck Sharp & Dohme; Novartis; Pfizer; Pierre Fabre; Regeneron; Roche
 
Luis Paz-Ares
Leadership - ALTUM Sequencing; Stab Therapeutics
Stock and Other Ownership Interests - Altum Sequencing; Stab therapeutics
Honoraria - Abbvie; Amgen; AstraZeneca; Bayer; BeOne; Boehringer Ingelheim; Bristol-Myers Squibb; Daiichi Sankyo; Gilead Sciences; GlaxoSmithKline; Janssen; Lilly; Medscape; Merck Serono; MSD; Novartis; Pfizer; PharmaMar; Regeneron; Roche/Genentech; Sanofi; Takeda
Consulting or Advisory Role - Abbvie; Amgen; Astellas Pharma; AstraZeneca; AstraZeneca; Bayer; BMS; GlaxoSmithKline; Janssen; Lilly; Merck; Mirati Therapeutics; MSD; Novartis; Pfizer; Pharmamar; Regeneron; Roche; Sanofi; Takeda
Speakers' Bureau - Amgen; AstraZeneca; Beone; BMS; Daiichi Sankyo Europe GmbH; Lilly; Merck Serono; MSD Oncology; Pfizer; Roche/Genentech
Research Funding - AstraZeneca (Inst); BMS (Inst); MSD (Inst); Pfizer (Inst); PharmaMar (Inst)
Other Relationship - Amgen (I); Astellas Pharma (I); Crinetics Pharmaceuticals (I); Esteve (I); HUTCHMED (I); Ipsen (I); ITM Isotope Technologies Munich (I); Merck (I); Novartis (I); Pfizer (I); Roche; Roche (I); Sanofi (I); SERVIER (I)
 
Caicun Zhou
Leadership - IASLC BOD
Honoraria - Akeso Biopharma; Alice; Amoy Diagnostics; Anheart Therapeutics; Hengrui Therapeutics; Innovent Biologics; Lilly; Luye Pharma; Merck Sharpe and Dohme; MSD; QiLu Pharmaceutical; Sanofi; TopAlliance BioSciences Inc
Consulting or Advisory Role - Amoy Diagnostics; Hengrui Therapeutics; Innovent Biologics; QiLu Pharmaceutical; Top Alliance BioScience
 
Afshin Dowlati
Consulting or Advisory Role - Abbvie/Stemcentrx; Amgen; AstraZeneca; Tempus
Research Funding - Abbvie/Stemcentrx (Inst); Amgen (Inst); Astellas Pharma (Inst); Bayer (Inst); Bicycle Therapeutics (Inst); Bristol-Myers Squibb (Inst); Gilead Sciences (Inst); Ipsen (Inst); Lilly/ImClone (Inst); Mirati Therapeutics (Inst); Seagen (Inst); Takeda (Inst)
 
Alissa Cooper
Honoraria - Ideology Health; Intellisphere; MedStar Health; MJH Life Sciences; Peer Direct; Physician's Education Resource, LLC
Consulting or Advisory Role - Amgen; Boehringer Ingelheim; Daiichi Sankyo/Astra Zeneca; Gilead Sciences; Novartis; Regeneron
Research Funding - Abbvie (Inst); Amgen (Inst); Daiichi Sankyo/Astra Zeneca (Inst); Merck (Inst); Monte Rosa Therapeutics (Inst); Roche (Inst)
Travel, Accommodations, Expenses - Gilead Sciences
 
Jair Bar
Consulting or Advisory Role - Abbvie; AstraZeneca; Bayer; BeiGene; Boehringer Ingelheim; Bristol-Myers Squibb; Genmab; Janssen Oncology; Medison; Merck Serono; MSD; Nectin Therapeutics; Novartis; Pfizer; Pfizer; Roche
Research Funding - Abbvie (Inst); AstraZeneca/MedImmune (Inst); Immunai (Inst); Janssen Oncology; MSD (Inst); Novartis (Inst); Oncohost (Inst); Roche (Inst); Takeda (Inst)
 
Se-Hoon Lee
Honoraria - Amgen; AstraZeneca/MedImmune; Bristol Myers Squibb Foundation; Lilly; Merck Sharp & Dohme; Roche; Yuhan
Consulting or Advisory Role - Abion; AstraZeneca; BeiGene; BMS/Ono; Daiichi Sankyo; IMBdx; ImmuneOncia; Janssen; Lilly; Merck (German); Merck Sharp & Dohme; Novartis; Pfizer; Roche; Takeda
Speakers' Bureau - Abion
Research Funding - AstraZeneca (Inst); Daiichi Sankyo; Lunit (Inst); Merck Sharp & Dohme (Inst)
 
Nadine Jahchan
Employment - Abbvie
Stock and Other Ownership Interests - Abbvie
Patents, Royalties, Other Intellectual Property - WO2020123664A1 - Methods of using anti-trem2 antibodies. US11572407B2 - Anti-MARCO antibodies and uses thereof
Travel, Accommodations, Expenses - Abbvie
 
Ye Zhao
Employment - Abbvie; BeiGene (I)
Stock and Other Ownership Interests - Abbvie; BeiGene (I)
 
Darius Meiman
Employment - Abbvie
Stock and Other Ownership Interests - Abbvie
Travel, Accommodations, Expenses - Abbvie
 
Fang Fang
Employment - Abbvie
Stock and Other Ownership Interests - Abbvie
Travel, Accommodations, Expenses - Abbvie
 
Guillermo Rivell
Employment - Abbvie
Stock and Other Ownership Interests - Abbvie
 
Tammy Palenski
Stock and Other Ownership Interests - Abbvie
 
Anne Chiang
Consulting or Advisory Role - Abbvie; Abbvie; Amgen; AstraZeneca; AstraZeneca; AstraZeneca; AstraZeneca; AstraZeneca; BMS; Boehringer Ingelheim; Catalyst Pharmaceuticals; Daichi; Flatiron Health; Fosun Pharma; Genentech; Genentech; Genentech; Genentech/Roche; Janssen Oncology; Jazz Pharmaceuticals; Jazz Pharmaceuticals; Merck; regeneron; Sanofi/Regeneron; Zai Lab
Research Funding - Abbvie; Amgen; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Lilly; Millennium; OncoMed; Onyx; Stem CentRx; Zai Lab
Travel, Accommodations, Expenses - Abbvie; AstraZeneca; Genentech/Roche